| Particulars (Rupees in Crores.) | Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 |
|---|---|---|---|---|---|
Gross Sales | 16,283.6 | 13,655.1 | 12,025.3 | 11,148.8 | 10,616.8 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 16,283.6 | 13,655.1 | 12,025.3 | 11,148.8 | 10,616.8 |
Other Operating Income | 430 | 358.5 | 544.4 | 316.4 | 189.7 |
Other Income | 188.9 | 147.5 | 148.8 | 2,664.2 | 153.5 |
Total Income | 16,902.5 | 14,161.1 | 12,718.5 | 14,129.4 | 10,960 |
Total Expenditure | 11,780.6 | 10,274 | 9,970.7 | 9,014.6 | 8,567.7 |
PBIDT | 5,121.9 | 3,887.1 | 2,747.8 | 5,114.8 | 2,392.3 |
Interest | 89.3 | 46.6 | 102.2 | 88.5 | 140 |
PBDT | 5,032.6 | 3,840.5 | 2,645.6 | 5,026.3 | 2,252.3 |
Depreciation | 677.9 | 558.8 | 544.1 | 550.7 | 523.6 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 1,058.7 | 1,027.7 | 460.6 | 323.8 | 338.1 |
Deferred Tax | -70 | -371.4 | -10 | 28.4 | -15.4 |
Reported Profit After Tax | 3,366 | 2,625.4 | 1,650.9 | 4,123.4 | 1,406 |
Minority Interest After NP | 74.3 | 49.5 | 70 | 75.1 | -5 |
Net Profit after Minority Interest | 3,354.6 | 2,677.2 | 1,663.7 | 4,089.9 | 1,454.6 |
Extra-ordinary Items | 0 | 1.13 | -4.67 | 2,405.58 | -104.99 |
Adjusted Profit After Extra-ordinary item | 3,354.6 | 2,676.07 | 1,668.37 | 1,684.32 | 1,559.59 |
EPS (Unit Curr.) | 33.34 | 26.45 | 16.33 | 39.95 | 14.21 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 100.6 | 101.2 | 101.2 | 102.4 | 102.4 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 31.45 | 28.46 | 22.85 | 45.87 | 22.53 |
PBDTM(%) | 30.9 | 28.12 | 22 | 45.08 | 21.21 |
PATM(%) | 20.67 | 19.22 | 13.72 | 36.98 | 13.24 |
The approval is valid for all Zydus Lifesciences affiliates and subsidiaries, said the company in the stock exchange filing dated March 10, 2025.
The approved strengths are 20 mg, 50 mg, 70 mg, 80 mg, 100 mg and 140 mg.
Here are some of the stocks that may see significant price movement today: TCS, Wipro, Zydus Lifesciences, RPP Infra Projects, etc.
The US market is a key growth driver for the company, accounting for almost 47% of Zydus Lifesciences' revenue.
Zydus Lifesciences announced it's Q3 FY25 and net profit grew by 30% YoY.
EBITDA for Q2 increased by 27.5% year-on-year to ₹1,461.4 crore, with EBITDA margins expanding by 170 basis points to 27.9%.
Here are some of the stocks that may see significant price movement today: Reliance Industries, HCLTech, Sunteck Realty, etc.
According to a regulatory filing by Zydus Lifesciences, the USFDA approved Paliperidone extended-release tablets.
Patients with metastatic castration-sensitive prostate cancer and castration-resistant prostate cancer are recommended to be treated with enzalutamide tablets.
The purchase will be on a slump sale basis, treating it as a going concern, with a cash-free and debt-free transaction at a lump-sum consideration of ₹840 million.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
